Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Almus

Drug and asset intelligence for Almus with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Aspar Pharmaceuticals Ltd →

Recent signals(1)

RegulatoryJune 24, 2026

Aspar Pharmaceuticals recalls Ibuprofen 200mg Tablets due to foil perforations

Aspar Pharmaceuticals Ltd is recalling specific batches of Ibuprofen 200mg Tablets due to foil perforations in some blisters.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Aspar Pharmaceuticals Ltd — Almus

Monitor for updates on the recall process and any regulatory actions taken against Aspar Pharmaceuticals.

June 24, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

NSAID →
Pain Management →
Pain Management · NSAID →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.